RemdesivirCovid-19: Gilead Pauses Access to Experimental Drug Due to “Overwhelming” Demand

Published 23 March 2020

Foster City, California-based Gilead Sciences said it has temporarily stopped granting patients access — with some exceptions — to remdesivir, the company’s experimental drug against the coronavirus which causes COVID-19. STAT reports that the company cited “overwhelming demand” as the reasons for the temporary suspension.